Skip to content
OpenCapital
Get started

Relmada Therapeutics, Inc. RLMD Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value at other companies

CHE
ChemedCHE
85.8-25.1%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$1.38-55.5%
HTF
Heartflow, Inc. Common StockHTFL
15.9+124%
Belden logo
BeldenBDC
$39.44+80.5%
KEE
Keel Infrastructure Corp. Common StockKEEL
$0.72-35.7%
Frequency Electronics logo
Frequency ElectronicsFEIM
$0.00—

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.

The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value?
Relmada Therapeutics, Inc. (RLMD) reported share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value of $1.38 in Q4 2025.
What does share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value mean?
The weighted average grant-date fair value of stock options or similar equity instruments awarded to employees during the reporting period. This provides insight into the cost basis of equity-based incentives and the company's approach to long-term compensation.